WO2001072280A3 - Microspheres for gene therapy - Google Patents

Microspheres for gene therapy Download PDF

Info

Publication number
WO2001072280A3
WO2001072280A3 PCT/US2001/009618 US0109618W WO0172280A3 WO 2001072280 A3 WO2001072280 A3 WO 2001072280A3 US 0109618 W US0109618 W US 0109618W WO 0172280 A3 WO0172280 A3 WO 0172280A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene therapy
angiogenic
microspheres
injectable compositions
present
Prior art date
Application number
PCT/US2001/009618
Other languages
French (fr)
Other versions
WO2001072280A2 (en
Inventor
Jean-Marie Vogel
Egisto Boschetti
Original Assignee
Biosphere Medical Inc
Vogel Jean Marie
Egisto Boschetti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosphere Medical Inc, Vogel Jean Marie, Egisto Boschetti filed Critical Biosphere Medical Inc
Priority to AU2001245987A priority Critical patent/AU2001245987A1/en
Priority to US10/220,983 priority patent/US20030212022A1/en
Publication of WO2001072280A2 publication Critical patent/WO2001072280A2/en
Publication of WO2001072280A3 publication Critical patent/WO2001072280A3/en
Priority to US11/253,435 priority patent/US20060063732A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) physically linked to a transfection agent for use in embolization gene therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.
PCT/US2001/009618 2000-03-24 2001-03-23 Microspheres for gene therapy WO2001072280A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001245987A AU2001245987A1 (en) 2000-03-24 2001-03-23 Compositions and methods for gene therapy
US10/220,983 US20030212022A1 (en) 2001-03-23 2001-03-23 Compositions and methods for gene therapy
US11/253,435 US20060063732A1 (en) 2000-03-24 2005-10-18 Compositions and methods for gene therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19190200P 2000-03-24 2000-03-24
US60/191,902 2000-03-24

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/253,435 Continuation US20060063732A1 (en) 2000-03-24 2005-10-18 Compositions and methods for gene therapy

Publications (2)

Publication Number Publication Date
WO2001072280A2 WO2001072280A2 (en) 2001-10-04
WO2001072280A3 true WO2001072280A3 (en) 2002-01-31

Family

ID=22707377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/009618 WO2001072280A2 (en) 2000-03-24 2001-03-23 Microspheres for gene therapy

Country Status (2)

Country Link
AU (1) AU2001245987A1 (en)
WO (1) WO2001072280A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951989B2 (en) 2009-04-09 2015-02-10 Actamax Surgical Materials, Llc Hydrogel tissue adhesive having reduced degradation time

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7332160B2 (en) 2002-07-12 2008-02-19 Boston Scientific Scimed, Inc. Medical device and method for tissue removal and repair
EP1559440B1 (en) * 2002-10-29 2015-09-23 Toray Industries, Inc. Vascular embolization meterial
FR2858628B1 (en) * 2003-08-04 2008-01-04 Polyplus Transfection NOVEL NUCLEIC ACID COMPLEXES FOR RNA INTERFERENCE AND THEIR USE FOR INHIBITING PROTEIN EXPRESSION
US8821859B2 (en) * 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
US8431114B2 (en) 2004-10-07 2013-04-30 Actamax Surgical Materials, Llc Polysaccharide-based polymer tissue adhesive for medical use
EP1844772A1 (en) * 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
CN101541857B (en) 2006-11-27 2012-12-12 阿克塔马克斯手术器材有限责任公司 Multi-functional polyalkylene oxide, hydrogel tissue adhesives
US8241609B2 (en) 2007-08-24 2012-08-14 E I Du Pont De Nemours And Company Method for embolization using liquid embolic materials
US8426492B2 (en) 2007-11-14 2013-04-23 Actamax Surgical Materials, Llc Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use
US8551136B2 (en) 2008-07-17 2013-10-08 Actamax Surgical Materials, Llc High swell, long-lived hydrogel sealant
WO2010017215A2 (en) * 2008-08-04 2010-02-11 The Regents Of The University Of California Biodegradable microspheres and methods of use thereof
US9044529B2 (en) 2008-11-19 2015-06-02 Actamax Surgical Materials, Llc Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
US8466327B2 (en) 2008-11-19 2013-06-18 Actamax Surgical Materials, Llc Aldehyde-functionalized polyethers and method of making same
US8580950B2 (en) 2009-07-02 2013-11-12 Actamax Surgical Materials, Llc Aldehyde-functionalized polysaccharides
WO2011002956A1 (en) 2009-07-02 2011-01-06 E. I. Du Pont De Nemours And Company Aldehyde-functionalized polysaccharides
US9758606B2 (en) 2012-07-31 2017-09-12 The Trustees Of Columbia University In The City Of New York Cyclopropenium polymers and methods for making the same
US8859705B2 (en) 2012-11-19 2014-10-14 Actamax Surgical Materials Llc Hydrogel tissue adhesive having decreased gelation time and decreased degradation time
EP3027659B1 (en) 2013-07-29 2020-12-09 Actamax Surgical Materials LLC Low swell tissue adhesive and sealant formulations
GB201315321D0 (en) 2013-08-28 2013-10-09 Koninklijke Nederlandse Akademie Van Wetenschappen Transduction Buffer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021327A1 (en) * 1991-05-29 1992-12-10 Sepracor, Inc. Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
WO1996011671A1 (en) * 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
EP0797988A2 (en) * 1993-07-19 1997-10-01 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
WO1999058694A1 (en) * 1998-05-12 1999-11-18 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021327A1 (en) * 1991-05-29 1992-12-10 Sepracor, Inc. Microspheres useful for therapeutic vascular occlusions and injectable solutions containing the same
EP0797988A2 (en) * 1993-07-19 1997-10-01 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
WO1996011671A1 (en) * 1994-10-12 1996-04-25 Focal, Inc. Targeted delivery via biodegradable polymers
WO1999058694A1 (en) * 1998-05-12 1999-11-18 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DASS C R (REPRINT) ET AL: "Microsphere -mediated targeted gene therapy of solid tumors", DRUG DELIVERY, (OCT-DEC 1999) VOL. 6, NO. 4, PP. 243-252. PUBLISHER: TAYLOR & FRANCIS INC, 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106. ISSN: 1071-7544., October 1999 (1999-10-01) - December 1999 (1999-12-01), HEART RES INST, CELL BIOL UNIT, 145 MISSENDEN RD, CAMPERDOWN, NSW 2050, AUSTRALIA (Reprint);CHARLES STURT UNIV, SCH BIOMED SCI, WAGGA WAGGA, NSW, AUSTRALIA, XP001030922 *
DASS, CRISPIN R. ET AL: "A microsphere -lipoplex (microplex) vector for targeted gene therapy of cancer. I. Construction and in vitro evaluation", DRUG DELIVERY (1999), 6(4), 259-269, - 1999, XP001030923 *
ESPOSITO E. ET AL: "Preparation and characterization of cationic microspheres for gene delivery.", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (1999) 189/1 (29-41)., - 1999, XP001030974 *
KALYANASUNDARAM S ET AL: "COACERVATE MICROSPHERES AS CARRIERS OF RECOMBINANT ADENOVIRUSES", CANCER GENE THERAPY, NORWALK, CT, US, vol. 6, no. 2, March 1999 (1999-03-01), pages 107 - 112, XP000904789, ISSN: 0929-1903 *
LUO DAN ET AL: "Controlled DNA delivery systems.", PHARMACEUTICAL RESEARCH (NEW YORK), vol. 16, no. 8, August 1999 (1999-08-01), pages 1300 - 1308, XP001030924, ISSN: 0724-8741 *
MATTHEWS C B ET AL: "POLY-L-LYSINE IMPROVES GENE TRANSFER WITH ADENOVIRUS FORMULATED IN PLGA MICROSPHERES", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 6, no. 9, September 1999 (1999-09-01), pages 1558 - 1564, XP000971877, ISSN: 0969-7128 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951989B2 (en) 2009-04-09 2015-02-10 Actamax Surgical Materials, Llc Hydrogel tissue adhesive having reduced degradation time

Also Published As

Publication number Publication date
WO2001072280A2 (en) 2001-10-04
AU2001245987A1 (en) 2001-10-08

Similar Documents

Publication Publication Date Title
WO2001072281A3 (en) Microspheres for active embolization
WO2001072280A3 (en) Microspheres for gene therapy
WO1999053943A3 (en) Therapeutic angiogenic factors and methods for their use
WO2003082188A3 (en) Methods and drug delivery systems for the treatment of orofacial diseases
WO2005079387A3 (en) Implantable drug delivery device including wire filaments
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
WO2002047731A3 (en) Drug delivery compositions and coated medical devices
WO2006002366A3 (en) Biodegradable ocular devices, methods and systems
WO1998029105A3 (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
TW200950764A (en) An intrauterine system
WO2002069848A3 (en) Apparatus for stent deployment with delivery of bioactive agents
EP0737703A3 (en) Hydrogel-forming , self-solvating absorbable polyester copolymers, and methods for use therefor
WO2005110436A3 (en) Macromolecule-containing sustained release intraocular implants and related methods
WO2002045431A3 (en) Genetically engineered herpes virus for the treatment of cardiovascular disease
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2002041837A3 (en) Treatment of mucositis
CA2235919A1 (en) Non-polymeric sustained release delivery system
NZ511984A (en) Controlled release formulation comprising GnRH-II
MXPA03010085A (en) Composition and methods for treatment of hyperplasia.
WO2007112195B1 (en) Intramedullary drug delivery device
MXPA02012666A (en) Topical pharmaceutical formulations and methods of treatment.
WO2002004623A3 (en) ANTISENSE COMPOSITIONS TARGETED TO β1 ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
WO2003032815A3 (en) Medical device for delivering patches
WO2001070289A3 (en) Injectable and swellable microspheres for tissue bulking
WO2003061578A3 (en) Compositions for treatment or prevention of bioterrorism

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10220983

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP